G. Steven Burrill

Chief Executive Officer at Burrill & Company

Biotech impressed investors with positive drug data, strong drug sales and earnings, and partnering deals.

Although the markets closed on a positive note in May, it will still take many more months before biotech starts on the road to full recovery.

Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.

Small biotechs were forced to restructure and downsize.

The meltdown in the financial markets represents a sea change in the world of financing that will continue to affect the flow of much needed capital into the sector for the foreseeable future.

The biotech industry's year-to-date report card contains good grades despite the turbulent economic climate.

Following the market crisis of the first quarter of 2008, biotech IPOs and financing are down, but partnering continues, and mergers and acquisitions (M&As) remain hot.

Despite the rising fears about a slowing economy, the biotech industry will continue to maintain its momentum this year.

Thirty years after the first biotechnology company opened, the sector is reaching a new level of maturity and globalization.